Global Artificial Intelligence (AI) Partnering Terms and Agreements 2010 to 2020

$3,495.00

The Global Artificial Intelligence (AI) Partnering Terms and Agreements 2010-2020 report provides comprehensive understanding and unprecedented access to the artificial intelligence partnering deals and agreements entered into by the worlds leading healthcare companies.

Publication date
November 2020
Number of pages
250+
Product type
Research report
Available formats
PDF document
Report edition
1
SKU
CP2125

The Global Artificial Intelligence Partnering Terms and Agreements 2010-2020 report provides an understanding and access to the artificial intelligence partnering deals and agreements entered into by the worlds leading healthcare companies.

 

  • Trends in artificial intelligence partnering deals
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Artificial intelligencepartnering contract documents
  • Top artificial intelligence deals by value

 

The Global Artificial Intelligence Partnering Terms and Agreements 2010-2020 report provides an understanding and access to the artificial intelligence partnering deals and agreements entered into by the worlds leading healthcare companies.

 

The report provides a detailed understanding and analysis of how and why companies enter artificial intelligencepartnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors artificial intelligencetechnology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. 

 

This report provides details of the latest artificial intelligence, oligonucletides including aptamers agreements announced in the healthcare sectors.  

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

 

This report contains a comprehensive listing of all artificial intelligence partnering deals announced since 2010 including financial terms where available including over 440 links to online deal records of actual artificial intelligence partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

 

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

For example, analyzing actual company deals and agreements allows assessment of the following:

 

  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What are the precise rights granted or optioned?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

 

The initial chapters of this report provide an orientation of artificial intelligence dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in artificial intelligence dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

 

Chapter 3 provides a review of the leading artificial intelligence deals since 2010. Deals are listed by headline value, signed by big pharma, most active artificial intelligence dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive listing of the top 25 most active companies in artificial intelligence dealmaking with a brief summary followed by a comprehensive listing of artificial intelligence deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 5 provides a comprehensive and detailed review of artificial intelligence partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

Chapter 6 lists artificial intelligence deals by technology type.

 

Chapter 7 provides a comprehensive and detailed review of artificial intelligence partnering deals signed and announced since Jan 2010. The chapter is organized by specific artificial intelligence technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

In addition, a comprehensive appendix is provided organized by artificial intelligence partnering company A-Z, deal type definitions and artificial intelligence partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in artificial intelligence partnering and dealmaking since 2010.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of artificial intelligence technologies and products.

 

Report scope

 

Global Artificial Intelligence Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to artificial intelligence trends and structure of deals entered into by leading companies worldwide.

 

Global Artificial Intelligence Partnering Terms and Agreements includes:

 

  • Trends in artificial intelligence dealmaking in the biopharma industry since 2010
  • Analysis of artificial intelligence deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life artificial intelligence deals
  • Access to over 440 artificial intelligence deals
  • The leading artificial intelligence deals by value since 2010
  • Most active artificial intelligence dealmakers since 2010
  • The leading artificial intelligence partnering resources

 

 In Global Artificial Intelligence Partnering Terms and Agreements, the available contracts are listed by:

 

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy and technology target

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. 

Global Artificial Intelligence Partnering Terms and Agreements provides the reader with the following key benefits:

 

  • In-depth understanding of artificial intelligence deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of artificial intelligence agreements with numerous real life case studies
  • Comprehensive access to over 440 actual artificial intelligence deals entered into by the world’s biopharma companies, together with real world clause examples
  • Full listing of  artificial intelligence deals by company A-Z, deal value, phase of development, deal type, and therapy focus
  • Identify leading artificial intelligence deals by value since 2010
  • Identify the most active artificial intelligence dealmakers since 2010
  • Detailed access to actual artificial intelligence contracts enter into by the leading 25 bigpharma
  • Insight into the terms included in artificial intelligence agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals          
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

 

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in artificial intelligence dealmaking

 

2.1. Introduction
2.2. Artificial intelligence partnering over the years
2.3. Most active artificial intelligence dealmakers
2.4. Artificial intelligence partnering by deal type
2.5. Artificial intelligence partnering by therapy area
2.6. Deal terms for artificial intelligence partnering
2.6.1 Artificial intelligence partnering headline values
2.6.2 Artificial intelligence deal upfront payments
2.6.3 Artificial intelligence deal milestone payments
2.6.4 Artificial intelligence royalty rates

 

Chapter 3 – Leading artificial intelligence deals

 

3.1. Introduction
3.2. Top artificial intelligence deals by value

 

Chapter 4 – Most active artificial intelligence dealmakers

 

4.1. Introduction
4.2. Most active artificial intelligence dealmakers
4.3. Most active artificial intelligence partnering company profiles

 

Chapter 5 – Artificial intelligence contracts dealmaking directory

 

5.1. Introduction
5.2. Artificial intelligence contracts dealmaking directory

 

Chapter 6 – Artificial intelligence dealmaking by technology type

 

Chapter 7 – Partnering resource center

 

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

 

Appendices

 

Appendix 1 – Artificial intelligence deals by company A-Z

 

Appendix 2 – Artificial intelligence deals by stage of development

 

Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation

 

Appendix 3 – Artificial intelligence deals by deal type

 

Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Research
Spin out
Sub-license
Supply
Technology transfer

 

Appendix 4 – Artificial intelligence deals by therapy area

 

Cardiovascular
Central Nervous System
Genetic disorders
Hematology
Immunology
Infectives
Metabolic
Musculoskeletal
Obstetrics
Oncology
Ophthalmics
Orphan disease
Pediatrics
Respiratory

 

Appendix 5 –Deal type definitions

 

About Wildwood Ventures

 

Current Partnering
Current Agreements
Recent report titles from Current Partnering

 

Table of figures

 

Figure 1: Artificial intelligence partnering since 2010
Figure 2: Active artificial intelligence dealmaking activity since 2010
Figure 3: Artificial intelligence partnering by deal type since 2010
Figure 4: Artificial intelligence partnering by disease type since 2010
Figure 5: Artificial intelligence deals with a headline value
Figure 6: Artificial intelligence deals with an upfront value
Figure 7: Artificial intelligence deals with a milestone value
Figure 8: Artificial intelligence deals with a royalty rate value
Figure 9: Top artificial intelligence deals by value since 2010
Figure 10: Most active artificial intelligence dealmakers since 2010
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events

Pricing options

  • $3,495: single-user
  • $5,245: multi-user
  • $10,495: single site license
  • $17,495: global site license

 

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

ST Biotherapeutics, 3Derm Systems, 23andMe, A*STAR Bioinformatics Institute, A.I. Squared, A2A Pharmaceuticals, Abramson Cancer Center, AcuraStem, Adapt Analytics, Adaptive Biotechnologies, Adents, Adventist Health, Adventus Ventures, Adynxx, Aether, Ai-Medic Devices, AiCure, Aiforia Technologies, AIkido Pharma, Aitrics, AKESOgen, Alberta Health Services, Alberta Innovates Bio Solutions, Alberta Innovates Technology Futures, Al Bio Tech, Alexion Pharmaceuticals, AlgoMedica, Align Technology, AliveCor, Alliance For Clinical Trials In Oncology, Almirall, ALS Association, AltaML, Althea Technologies, Alverno Clinical Laboratories, Amazon Web Services, American Sleep Apnea Association, Amgen, Amitech Solutions, Amyris, Analytics Engines, AnchorDx, Anthem, Applied BioMath, ArcherDX, Arctoris, Ares Genetics, Arm, Arterys, ARUP Laboratories, Asimily, Astellas Pharma, AstraZeneca, Atomwise, Atrapos Therapeutics, ATUM, AUM Biotech, Auransa, Auron Therapeutics, Automation Anywhere, Avera Health, AXA PPP healthcare, Ayasdi, BAMF Health, BASF, Bausch & Lomb, Bayer, Bay Labs, BCG Digital Ventures, BC Platforms, Beckman Coulter, Becton Dickinson, Beijing Tide Pharmaceutical, BenevolentAI, Benson Hill Biosystems, Berg, BERG Analytics, Berg Pharma, Bill and Melinda Gates Foundation, BioBeats, BioBright, Biocept, BioDuro, Biofourmis, Biomedical Advanced Research and Development Authority, BioMotiv, Biorelate, BioSig Technologies, BioSymetrics, Bioz, Bird Foundation, Blackford, BlackThorn Therapeutics, Blockshine Technology, Bloqcube, Body Labs, Boehringer Ingelheim, BostonGene, Brainomix, BrainScope, Bridge Biotherapeutics, Brigham and Women's Hospital, Bristol-Myers Squibb, Broad Institute, Brown University, BullFrog AI, BurstIQ, C4X Discovery, California Institute for Biomedical Research, Cancer Genetics, Cancer Research UK, Cannabics Pharmaceuticals, Canopy Biosciences, Cardinal Analytx Solutions, Cardiowise, Caresyntax, Carnegie Mellon University, CAS, Ceapro, Celgene, Cellgen Diagnostics, Center for Prostate Disease Research, Centers for Medicare and Medicaid Services, Centogene, Centre Leon Berard, Cerevel Therapeutics, Cernostics, Certis, Charles River Laboratories, CHDI Foundation, ChemDiv, Chemi Pharmaceutical, Children's Hospital Boston, Children's Hospital of Philadelphia, Children's National Health System, Children’s Center for Cancer and Blood Diseases (CCCBD), China Oncology Focus, Christian Doppler Research Association, City of Hope, Claritas HealthTech, Cleveland Clinic, CLEW Medical, Client Outlook, Clinical Research Strategies, Clinigen, Cloudera, Cloud Pharmaceuticals, Cogia Biotech, Cognetivity Neurosciences, Cognoa, Cohen Veterans Bioscience, Columbia University, Concerto HealthAI, Consortium AI, Control Flo Medical, COPAN, CoreBiome, Covaris, Crothall Healthcare Technology Solutions, CrystalGenomics, CureMetrix, Cures Within Reach, Current Health, Cyclica, Cytobank, CytoReason, Dacadoo, Daewoong Pharmaceutical, Dana-Farber Cancer Institute, DarwinHealth, Dascena, DASH Analytics, Data2Life, DataRobot, Datavant, DEARhealth, Deciphex, DecisionQ, DEEP 6 AI, Deep Cube, Deep Lens, Defense Advanced Research Projects Agency, Defense Threat Reduction Agency, Definiens, Department of Defense, Department of Energy, Department of Veterans Affairs, DePuy, Desktop Genetics, Diagnos, Diagnostic Robotics, DiA Imaging Analysis, Diurnal, Draper Laboratories, Drugs for Neglected Diseases Initiative, Duality Technologies, e-NIOS, E-Therapeutics, Early Signal Foundation, Edison Nation, Edwards Lifesciences, eKare, Eko, Elevian, Eli Lilly, Elucidata, Emory University, Empirico, Enamine, Endpoint Health, EndPoint Technologies, EnvoyAI, Esaote, European Board and College of Obstetrics and Gynaecology, Evidation Health, Evotec, Ewha Womans University, Excelra, ExScientia, Fabric Genomics, FDNA, Fio, Flo Health, Food and Drug Administration (FDA), Freenome, Fresenius Medical Care, Fujifilm medical systems, Fujitsu Laboratories, Fujitsu Laboratories of America, Fusion Antibodies, Garuda Health Services, Gatehouse Bio, GC Pharma, GDM Seeds, GE Healthcare, Geisinger Health System, Genentech, Genetic Technologies, Geneva University Hospitals, GenomeSmart, Genomics, Genomics England, Genomic Testing Cooperative, Genpact, Georgia Institute of Technology, German Research Center for Artificial Intelligence, Gestalt Diagnostics, Getinge, Gilead Sciences, Ginkgo BioWorks, Glassbeam, GlaxoSmithKline, Global Good Fund, Gnosis Bioresearch, GNS Healthcare, Google, Govzilla, Greenville Health System, GT Apeiron Therapeutics, Guerbet, Haga Teaching Hospital, Halo Dx, Hancom Group, Happy Life Tech, Harvard University, Healius, HealthCare Konnect, HealthLytix, HealthPointe Solutions, Health Services Advisory Group, Healx, Helsinki University Central Hospital (HUCH) Comprehensive Cancer Center, Henry M. Jackson Foundation, Hill-Rom, Hitachi, Horizon Discovery, Huawei, Humana, Human Longevity, I-Dante, Ibex Medical Analytics, iBio, IBM, IBM Watson Health, IDx, iFLYTEK, Iktos, Illumina, Image Analysis, Imagia, Imalogix, Immuneering, InContext.ai, INC Research, Indivumed, Ingenza, Innoplexus, Innovate UK, Innovative Medicines Initiative (IMI), Inovalon, Inova Translational Medicine Institute, Insel Gruppe, Insilico, Insilico Medicine, Insitro, Institute of Cancer Research, Integra LifeSciences, Intel, Intellegens, Interprotein, InterSystems, inviCRO, Ionis Pharmaceuticals, IQVIA, Iris Pharma, IrisVision, IronHealth, Israeli National Authority for Technological Innovation, Itus, Janssen Alzheimer Immunotherapy, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Japan Agency for Medical Research and Development, J Craig Venter Institute, Jewish General Hospital, Jiangsu Chia Tai Tianqing Pharmaceutical, Jiangsu Hansoh Pharmaceutical, Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Innovation, John Wiley and Sons, Juvenescence, Jvion, Kaiser Permanente, Kantar Health, Karuna Therapeutics, KBP BioSciences, Kebotix, Keen Eye, KemPharm, Kings College London, Kirin, Konica Minolta, KYAN Therapeutics, Kyoto University, Laboratory Corporation of America, Labrador Technologies, LabTwin, La Jolla Institute for Allergy & Immunology, Lark Technologies, Leidos Holdings, Les Laboratoires Servier, Lieber Institute, LifeArc, Life Image, Lumme, Lundbeck, Lunit, Lygos, MAbSilico, Mach7 Technologies, Mannin Research, Massachusetts General Hospital, Massachusetts Institute of Technology, Massachusetts Life Sciences Center, Mateon Therapeutics, Max-Planck, MaxQ AI, Mayo Clinic, McGill University, Medable, Medial, Medial EarlySign, MEDIAN Technologies, Medical University of Graz, Medicines and Healthcare Products Regulatory Agency, Medidata Solutions, Medipath, MediTechnix, Medopad, MedyMatch, Melax Technologies, Memorial Sloan Kettering Cancer Center, Mendel.ai, Mendel Health, Merck KGaA, Meridian IT, Metaoptima Technology, Michael J Fox Foundation, Michigan State University, Microsoft, MILA International, Milner Therapeutics Institute and Consortium, MindPeak, Mindstrong Health, MITRE, Mitsui, Molecular Health, Molplex Pharmaceuticals, Monsanto, MORE Health, Motic, Mount Sinai Health System, Multiple Myeloma Research Foundation, Mundipharma, MyHealios, Myovant Sciences, Myriad Genetics, Nankai Hospital, Nano-X Imaging, Nano Global, National Cancer Center of Japan, National Center for Advancing Translational Sciences (NCATS), National Center for Tumor Diseases, National Healthcare Services (NHS), National Heart, Lung and Blood Institute, National Institute of Allergy and Infectious Diseases, National Institute on Aging, National Institutes of Health, National Science Foundation, National University of Singapore, NEC, Neiman Institute, NeoX Biotech, Nestle, NetraMark, NetraPharma, NeuroLogica, Neuropore Therapies, New England Biolabs, New Jersey Innovation Institute, Nference, NHS Scotland, Nico, NorthBay Healthcare, Northeastern University, Northern Arizona Healthcare, Northwestern Medicine Bluhm Cardiovascular Institute, Norwegian Research Council, Novant Health, Novartis, NTT Data, NTT Medical Center Tokyo, Nuance Healthcare, Nucleai, NuMedii, Numerate, Nuritas, Nvidia, Nyansa, NYU Langone Medical Center, OKRA Technologies, Olea Medical, Omnicell, Oncodesign, OncoHost, OncoStatyx, One Drop, Onegevity, OnFace, Ono Pharmaceutical, Open Commons Consortium, Optibrium, Optima Solutions Holdings, OptraHEALTH, Origenis, OSE Immunotherapeutics, Oslo University Hospital, Owkin, Oxford Genetics, Oxford Sciences Innovation, Paige, Pancreatic Cancer Collective, Parallax Health Sciences, Pareto Biotechnologies, Parexel, Parkinson's Institute, PathAI, Pathway Genomics, Penn Medicine, Pennsylvania Department of Health, PeptiDream, PercayAI, PeriGen, PerkinElmer, Pfenex, Pfizer, PGI Drug Discovery, Pharnext, Phenome Networks, Phenomics Health, PhoreMost, PhysIQ, PicnicHealth, Ping An Ventures, Pluristem Therapeutics, PolarisQB, Porton Pharma Solutions, PPD, Precera Bioscience, Precision Innovation Network, Premier Health Group, Prescient Medical, PrimeVigilance, Procter & Gamble, Prognos, Proscia, Protagen, Protean BioDiagnostics, Proteona, Protxx, PsychoGenics, Purdue Research Foundation, Qiagen, Qu & Co, Qure.ai, R1 RCM, Radiology Oncology Systems, RadNet, Rady Children's Institute for Genomic Medicine, RayBiotech, ReadCoor, Recursion, Regenstrief Institute, Reified Capital, Relation Therapeutics, Relay Medical, Reliq Health, RenalytixAI, RENX AI Labs, Repurpose.AI, Research Institute of McGill University Health Centre (RI MUHC), Reveal Biosciences, Reverie Labs, ReviveMed, Revive Therapeutics, Revon Systems, Rhythm Pharmaceuticals, Roam Analytics, Roche, Royal Philips Electronics, Rush University Medical Center, Saama, Salud Digna, Salud Interactiva, Samsung Electronics, Sanofi, Santen, Sanuwave Health, Sartorius, Schrodinger, Scripps Research Institute, Second Genome, Sectra, Seedo, Selah Genomics, Selecta Biosciences, Sema4, SEngine Precision Medicine, Sensyne Health, Serametrix, Seven Bridges Genomics, Sheikh Zayed Institute for Pediatric Surgical Innovation, Siemens Healthineers, SilverCloud Health, SK Biopharmaceuticals, SmartAction, snap40, Socionext, SOINN, SomaLogic, SOM Biotech, Sonoma Orthopedic Products, Sonora Quest Laboratories, Sophia Genetics, Soricimed Biopharma, Spanish National Cancer Research Centre, Splice Machine, Standigm, Stanford University, Stanford University School of Medicine, StemoniX, Stonehaven Incubate, Sun Yat-sen University, Susan G. Komen for the Cure, Synchronous Health, Syneos Health, Takeda Pharmaceutical, TARA Biosystems, Techcyte, TELUS Ventures, Tempus, Tencent Holdings, TenX Biopharma, TeraRecon, Terason, Teva Pharmaceutical Industries, TheraSim, The University of Chicago Medicine, ThinkCyte, Thomson Reuters, Tissue Analytics, Topcon, Transgene, Translational Drug Development, Trethera, TTP Group, Twist Bioscience, twoXAR, Ubic, UCB, UiPath, Ultivue, UMass Memorial Medical Center, uMETHOD Health, Uniformed Services University of the Health Sciences, United Imaging Healthcare, Universite Laval, University Medical Center Groningen, University Medical Center Utrecht, University of California, Davis, University of California, San Diego, University of California Los Angeles, University of California San Francisco, University of Connecticut, University of Hong Kong, University of Maryland Baltimore, University of Miami, University of Michigan, University of Montreal, University of Oxford, University of Pittsburgh, University of Quebec, University of Sherbrooke, University of the Highlands and Islands, University of Tokyo, UPMC, US Veterans Administration, Utah Genome Project, Valeant Pharmaceuticals, Valisure, Vanderbilt University, Varian Medical Systems, VeChain, Veeva Systems, Verb Surgical, Vertex Pharmaceuticals, Vida Diagnostics, VieCure, Vir Biotechnology, Visage Imaging, VisiQuate, Vitaccess, VitalConnect, Viviphi, Viz.ai, WakeMed Health & Hospitals, Walter Reed Army Institute of Research, Ward Medication Management, Warp Drive Bio, Washington University in St Louis, Whiterabbit, Windber Research Institute, WinterLight Labs, World Health Organization, Worldwide Clinical Trials, Worthington Biochemical Corporation, Wound Care Advantage, Wuxi Apptec Laboratory Services, WuXi NextCODE Genomics, Wyss Institute, X-chem, Xencor, Xenon Pharmaceuticals, XtalPi, Yale School of Medicine, Yuhan Corporation, ZebiAI Therapeutics, Zebra Medical Vision

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.